Company news

Castle Biosciences, Inc. news in 2022

Castle Biosciences, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

November 20, 2022

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

November 16, 2022

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

November 14, 2022

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

November 13, 2022

Castle Biosciences Announces Third Quarter 2022 Results

November 1, 2022

Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma

October 30, 2022

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

October 26, 2022

New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone

October 24, 2022

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors

October 23, 2022

New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure

October 19, 2022

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

October 18, 2022

Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

October 12, 2022

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting

October 10, 2022

Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

October 9, 2022

Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma

September 22, 2022

Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference

September 20, 2022

Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day

September 19, 2022

Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association

September 12, 2022

Castle Biosciences to Host Investor Day on Sept. 20, 2022

August 23, 2022

Castle Biosciences Reports Second Quarter 2022 Results

August 7, 2022

American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus

August 3, 2022

Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 2, 2022

DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma

July 24, 2022

Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8

July 24, 2022

Castle Biosciences Honored with a 2022 Arizona Top Workplace Award

July 17, 2022

Castle Biosciences Announces Support for OHSU’s War on Melanoma™

June 19, 2022

Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award

May 26, 2022

Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC

May 18, 2022

Castle Biosciences Reports First Quarter 2022 Results

May 8, 2022

Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests

April 28, 2022

Castle Biosciences Completes Acquisition of AltheaDx

April 25, 2022

Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9

April 24, 2022

Castle Biosciences to Acquire AltheaDx

April 3, 2022

Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)

March 28, 2022

Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results

February 27, 2022

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022

February 13, 2022

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases

February 2, 2022

Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award

February 1, 2022

Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022

January 23, 2022

Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma

January 11, 2022

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results

January 9, 2022

Calls in 2022

Decks in 2022